R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 52.99
+1.85 (3.62%)
Jul 14, 2026, 4:00 PM EDT
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 5.09 billion as of July 14, 2026. Its market cap has increased by 7.57% in one year.
Market Cap
5.09B
Enterprise Value
3.38B
Revenue
896.26M
Ranking
n/a
PE Ratio
37.81
Stock Price
52.99
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has decreased from 5.40B to 5.09B, a decrease of -5.81%. That is a compound annual growth rate of -1.50%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 14, 2026 | 5.09B | -10.22% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Beijing Konruns Pharmaceutical | 5.66B |
| PharmaResources (Shanghai) | 5.52B |
| Novogene | 5.35B |
| Hangzhou Biotest Biotech | 5.29B |
| Wuhan Hvsen Biotechnology | 4.89B |
| Shenzhen Weiguang Biological Products | 4.81B |
| Zhejiang Wecome Pharmaceutical Company | 4.80B |
| Xiangxue Pharmaceutical | 4.77B |